Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
13.10
+0.75 (6.07%)
At close: Jul 16, 2025, 4:00 PM
13.07
-0.03 (-0.23%)
After-hours: Jul 16, 2025, 4:09 PM EDT
Zenas BioPharma Stock Forecast
Stock Price Forecast
The 7 analysts that cover Zenas BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $32.29, which forecasts a 146.49% increase in the stock price over the next year. The lowest target is $19 and the highest is $45.
Price Target: $32.29 (+146.49%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 16, 2025.
Analyst Ratings
The average analyst rating for Zenas BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +129.01% | May 16, 2025 |
| Wedbush | Wedbush | Buy Initiates $35 | Buy | Initiates | $35 | +167.18% | Mar 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +243.51% | Mar 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +129.01% | Mar 12, 2025 |
| Wolfe Research | Wolfe Research | Buy Initiates $19 | Buy | Initiates | $19 | +45.04% | Feb 4, 2025 |
Financial Forecast
Revenue This Year
13.26M
from 5.00M
Increased by 165.20%
Revenue Next Year
21.71M
from 13.26M
Increased by 63.75%
EPS This Year
-4.35
from -11.89
EPS Next Year
-4.09
from -4.35
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 26.3M | 89.3M | 147.3M |
| Avg | 13.3M | 21.7M | 54.8M |
| Low | 9.8M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 425.0% | 573.1% | 578.5% |
| Avg | 165.2% | 63.7% | 152.2% |
| Low | 96.0% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -3.87 | -2.89 | -3.12 |
| Avg | -4.35 | -4.09 | -3.91 |
| Low | -5.30 | -5.09 | -4.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.